

## DAFTAR PUSTAKA

- Adiwinata, R. *et al.* (2015) 'TINJAUAN PUSTAKA Tatalaksana Terkini Perlemakan Hati Non Alkoholik', *Jurnal Penyakit Dalam Indonesia*.
- Aguirre, L. *et al.* (2011) 'Beneficial effects of quercetin on obesity and diabetes', *Open Nutraceuticals Journal*. doi: 10.2174/1876396001104010189.
- Amato, A. *et al.* (2017) 'NAFLD and atherosclerosis are prevented by a natural dietary supplement containing curcumin, silymarin, guggul, chlorogenic acid and inulin in mice fed a high-fat diet', *Nutrients*. doi: 10.3390/nu9050492.
- Anand David, A. V., Arulmoli, R. and Parasuraman, S. (2016) 'Overviews of biological importance of quercetin: A bioactive flavonoid', *Pharmacognosy Reviews*. doi: 10.4103/0973-7847.194044.
- Antunes, C., Azadfard, M., Hoilat, G. J., & Gupta., M. (2020). *Fatty Liver*. StatPearls Publishing. Retrieved November 18, 2020, from <https://www.ncbi.nlm.nih.gov/books/NBK441992/?report=classic>.
- Asrani, S. K. *et al.* (2019) 'Burden of liver diseases in the world', *Journal of Hepatology*. doi: 10.1016/j.jhep.2018.09.014.
- Bellentani, S. *et al.* (2010) 'Epidemiology of non-alcoholic fatty liver disease', *Digestive Diseases*. doi: 10.1159/000282080.
- Byrne, C. D. and Targher, G. (2015) 'NAFLD: A multisystem disease', *Journal of Hepatology*. doi: 10.1016/j.jhep.2014.12.012.
- Das C, Lucia MS, H. K. and T. J. (2017) '乳鼠心肌提取 HHS Public Access', *Physiology & behavior*, 176(3), pp. 139–148. doi: 10.1016/j.gtc.2016.07.003.Non-alcoholic.
- Gedikli, S. *et al.* (2017) 'Preventive effects of quercetin on liver damages in high-fat diet-induced obesity', *Journal of Histology and Histopathology*. doi: 10.7243/2055-091x-4-7.
- Hamaguchi, M. *et al.* (2012) 'Aging is a risk factor of nonalcoholic fatty liver

- disease in premenopausal women’, *World Journal of Gastroenterology*. doi: 10.3748/wjg.v18.i3.237.
- Jan, A. T. *et al.* (2010) ‘Dietary flavonoid quercetin and associated health benefits- An overview’, *Food Reviews International*. doi: 10.1080/87559129.2010.484285.
- Kelly, G. S. (2011) ‘Quercetin. Monograph.’, *Alternative medicine review: a journal of clinical therapeutic*.
- Kim, C. S. *et al.* (2015) ‘Quercetin reduces obesity-induced hepatosteatosis by enhancing mitochondrial oxidative metabolism via heme oxygenase-1’, *Nutrition and Metabolism*. doi: 10.1186/s12986-015-0030-5.
- Kulczyński, B., Gramza-Michałowska, A. and Sidor, A. (2017) ‘Quercetin – a flavonoid with a high health-promoting potential’, *Nauka Przyroda Technologie*, 10(3). doi: 10.17306/j.npt.2016.3.29.
- Labrecque, D. R. *et al.* (2014) ‘World gastroenterology organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis’, *Journal of Clinical Gastroenterology*. doi: 10.1097/MCG.000000000000116.
- Lakhanpal, P. and Rai, D. K. (2007) ‘Quercetin: A Versatile Flavonoid’, *Internet Journal of Medical Update - EJOURNAL*, 2(2). doi: 10.4314/ijmu.v2i2.39851.
- Li, W. and Alazawi, W. (2020) ‘Non-alcoholic fatty liver disease’, *Clinical medicine (London, England)*. doi: 10.7861/clinmed.2020-0696.
- LI, X. *et al.* (2013) ‘Quercetin improves insulin resistance and hepatic lipid accumulation in vitro in a NAFLD cell model’, *Biomedical Reports*. doi: 10.3892/br.2012.27.
- Li, Y. *et al.* (2016) ‘Quercetin, inflammation and immunity’, *Nutrients*. doi: 10.3390/nu8030167.

- Longo, D. L. (2015) *Harrison Principle of Internal Medicine, Harrison Principle of Internal Medicine*.
- Marcuccilli, M. and Chonchol, M. (2016) 'NAFLD and chronic kidney disease', *International Journal of Molecular Sciences*. doi: 10.3390/ijms17040562.
- Mengist, W., Soromessa, T. and Legese, G. (2020) 'Method for conducting systematic literature review and meta-analysis for environmental science research', *MethodsX*. doi: 10.1016/j.mex.2019.100777.
- Mlcek, J. *et al.* (2016) 'Quercetin and its anti-allergic immune response', *Molecules*. doi: 10.3390/molecules21050623.
- Panchal, S. K., Poudyal, H. and Brown, L. (2012) 'Quercetin ameliorates cardiovascular, hepatic, and metabolic changes in diet-induced metabolic syndrome in rats', *Journal of Nutrition*. doi: 10.3945/jn.111.157263.
- Porras, D. *et al.* (2017) 'Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation', *Free Radical Biology and Medicine*. Elsevier, 102(September), pp. 188–202. doi: 10.1016/j.freeradbiomed.2016.11.037.
- Qin, G. *et al.* (2018) 'Isoquercetin improves hepatic lipid accumulation by activating AMPK pathway and suppressing TGF- $\beta$  signaling on an HFD-induced nonalcoholic fatty liver disease rat model', *International Journal of Molecular Sciences*. doi: 10.3390/ijms19124126.
- Shamseer, L. *et al.* (2015) 'Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015: Elaboration and explanation', *BMJ (Online)*, 349(January), pp. 1–25. doi: 10.1136/bmj.g7647.
- Smith, A. J. *et al.* (2016) 'Quercetin: A Promising Flavonoid with a Dynamic Ability to Treat Various Diseases, Infections, and Cancers', *Journal of Cancer Therapy*. doi: 10.4236/jct.2016.72010.

- Smith, B. W. and Adams, L. A. (2011) 'Non-alcoholic fatty liver disease', *Critical Reviews in Clinical Laboratory Sciences*. doi: 10.3109/10408363.2011.596521.
- Sokolová, R. *et al.* (2012) 'The oxidation of natural flavonoid quercetin', *Chemical Communications*. doi: 10.1039/c2cc18018a.
- Sumida, Y. and Yoneda, M. (2018) 'Current and future pharmacological therapies for NAFLD/NASH', *Journal of Gastroenterology*. Springer Japan, 53(3), pp. 362–376. doi: 10.1007/s00535-017-1415-1.
- Surapaneni, K. M. and Jainu, M. (2014) 'Comparative effect of pioglitazone, quercetin and hydroxy citric acid on the status of lipid peroxidation and antioxidants in experimental non-alcoholic steatohepatitis', *Journal of Physiology and Pharmacology*, 65(1), pp. 67–74.
- Takahashi, Y. and Fukusato, T. (2014) 'Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis', *World Journal of Gastroenterology*, 20(42), pp. 15539–15548. doi: 10.3748/wjg.v20.i42.15539.
- Ter Horst, K. W. and Serlie, M. J. (2017) 'Fructose consumption, lipogenesis, and non-alcoholic fatty liver disease', *Nutrients*. doi: 10.3390/nu9090981.
- The Joanna Briggs Institute (2017) 'Checklist for Quasi-Experimental Studies', *The Joanna Briggs Institute*.
- Wang, L., Guo, J. and Lu, J. (2016) 'Risk factor compositions of nonalcoholic fatty liver disease change with body mass index in males and females', *Oncotarget*. doi: 10.18632/oncotarget.9691.
- Wang, L. L. *et al.* (2016) 'Amelioration of free fatty acid-induced fatty liver by quercetin-3-O- $\beta$ -D-glucuronide through modulation of peroxisome proliferator-activated receptor- $\alpha$ /sterol regulatory element-binding protein-1c signaling', *Hepatology Research*, 46(2), pp. 225–238. doi: 10.1111/hepr.12557.

- Wang, W. *et al.* (2013) ‘Quercetin and allopurinol reduce liver thioredoxin-interacting protein to alleviate inflammation and lipid accumulation in diabetic rats’, *British Journal of Pharmacology*. doi: 10.1111/bph.12226.
- Xiao, J. *et al.* (2019) ‘Global liver disease burdens and research trends: Analysis from a Chinese perspective’, *Journal of Hepatology*. doi: 10.1016/j.jhep.2019.03.004.
- Xu, D. *et al.* (2019) ‘Antioxidant activities of quercetin and its complexes for medicinal application’, *Molecules*. doi: 10.3390/molecules24061123.
- Xu, Y. *et al.* (2019) ‘Metabolomics characterizes the effects and mechanisms of quercetin in nonalcoholic fatty liver disease development’, *International Journal of Molecular Sciences*. doi: 10.3390/ijms20051220.